ArticleMedical oncology (Northwood, London, England)2011
The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib.
Article in Medical oncology (Northwood, London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 46 citations in OpenAlex.
- Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment.Scientific reports · 2015Trial
- A Systematic Intracranial Exposure-Response Evaluation of Brain-Penetrant Inhibitors: Informing Dose Selection for Brain Metastases.Clinical and translational science · 2026Article
- Modeling exposure-driven adverse events of EGFR TKIs in the treatment of patients with non-small cell lung cancer.Acta pharmacologica Sinica · 2025Article
- Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.Clinical pharmacokinetics · 2023Review
- Precision Dosing of Targeted Therapies Is Ready for Prime Time.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Therapeutic drug monitoring of oral targeted antineoplastic drugs.European journal of clinical pharmacology · 2021Review
- Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma.Analytical and bioanalytical chemistry · 2021Article
- Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer.Translational oncology · 2021Article
- ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib.Investigational new drugs · 2020Article
- FDA- and EMA-Approved Tyrosine Kinase Inhibitors in AdvancedBiomolecules · 2019Review
- Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib.CPT: pharmacometrics & systems pharmacology · 2019Article
- Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.Clinical pharmacology and therapeutics · 2017Review
- Therapeutic drug monitoring and tyrosine kinase inhibitors.Oncology letters · 2016Article
- The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations.Scientific reports · 2015Article
- Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Clinical pharmacokinetics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to explore the relationship between gefitinib exposure and clinical outcome in gefitinib-treated patients with advanced non-small cell lung cancer. Thirty patients participated in this pharmacokinetic study and received 250-mg oral doses of gefitinib once daily. Blood samples were collected before dosing and on days 7, 14, 21, and 28. The plasma concentrations of gefitinib were evaluated using a validated high-performance liquid chromatographic method with tandem mass spectrometric detection. Univariate and multivariate analyses were performed to determine predictive factors for response and survival of patients. EGFR mutations were analyzed retrospectively. Median survival time (MST) was 9.97 months (95%CI 2.79-17.14 months). The geometric mean trough gefitinib plasma concentration (Cminss was 266 ng/ml (range 94-538 ng/ml). In the multivariate analysis, only skin rash was associated with gefitinib-induced disease control (P=0.017); Adenocarcinoma, skin rash, and 'high' Cminss (Cminss≥200 ng/ml) were independently associated with overall survival (P=0.004, 0.028,0.007, respectively). MST of EGFR wild-type patients with 'high' Cminsswas longer than that with 'low' Cminss (P=0.002). Our study results show that pharmacokinetic variability may also account for the different outcomes following treatment with gefitinib for patients with wild-type EGFR. Further studies are needed to confirm these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.